Arora A - Search Results

1

Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age.

Zedda L, Forleo-Neto E, Vertruyen A, Raes M, Marchant A, Jansen W, Clouting H, Arora A, Beatty ME, Galli G, Del Giudice G, Castellino F. Zedda L, et al. Among authors: arora a. Pediatr Infect Dis J. 2015 Jan;34(1):73-8. doi: 10.1097/INF.0000000000000465. Pediatr Infect Dis J. 2015. PMID: 25037034 Clinical Trial.

2

Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study.

Alberer M, Burchard G, Jelinek T, Reisinger E, Beran J, Meyer S, Forleo-Neto E, Gniel D, Dagnew AF, Arora AK. Alberer M, et al. Travel Med Infect Dis. 2014 Sep-Oct;12(5):485-93. doi: 10.1016/j.tmaid.2014.04.011. Epub 2014 May 9. Travel Med Infect Dis. 2014. PMID: 24873986 Clinical Trial.

3

Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.

Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G. Knuf M, et al. Among authors: arora a. Pediatr Infect Dis J. 2014 Dec;33(12):e320-9. doi: 10.1097/INF.0000000000000462. Pediatr Infect Dis J. 2014. PMID: 24978857 Clinical Trial.

4

Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.

Frey SE, Reyes MR, Reynales H, Bermal NN, Nicolay U, Narasimhan V, Forleo-Neto E, Arora AK. Frey SE, et al. Vaccine. 2014 Sep 3;32(39):5027-34. doi: 10.1016/j.vaccine.2014.07.013. Epub 2014 Jul 18. Vaccine. 2014. PMID: 25045825 Clinical Trial.

5

Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.

Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G. Knuf M, et al. Among authors: arora a. Vaccine. 2015 Jan 1;33(1):174-81. doi: 10.1016/j.vaccine.2014.10.085. Epub 2014 Nov 11. Vaccine. 2015. PMID: 25444803 Free article. Clinical Trial.

6

Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.

Alberer M, Burchard G, Jelinek T, Reisinger EC, Meyer S, Forleo-Neto E, Dagnew AF, Arora AK. Alberer M, et al. J Travel Med. 2015 Mar-Apr;22(2):105-14. doi: 10.1111/jtm.12180. Epub 2014 Dec 7. J Travel Med. 2015. PMID: 25483566 Free article. Clinical Trial.

7

Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.

Vesikari T, Forstén A, Arora A, Tsai T, Clemens R. Vesikari T, et al. Among authors: arora a. Hum Vaccin Immunother. 2015;11(8):2102-12. doi: 10.1080/21645515.2015.1044167. Hum Vaccin Immunother. 2015. PMID: 26091244 Free PMC article. Clinical Trial.

8

MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico.

Cruz-Valdez A, Valdez-Zapata G, Patel SS, Castelli FV, Garcia MG, Jansen WT, Arora AK, Heijnen E. Cruz-Valdez A, et al. Among authors: arora ak. Hum Vaccin Immunother. 2018 Feb 1;14(2):386-395. doi: 10.1080/21645515.2017.1373227. Epub 2018 Jan 3. Hum Vaccin Immunother. 2018. PMID: 28925801 Free PMC article. Clinical Trial.

9

Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.

Alberer M, Burchard G, Jelinek T, Reisinger E, Beran J, Hlavata LC, Forleo-Neto E, Dagnew AF, Arora AK. Alberer M, et al. J Travel Med. 2015 Jan-Feb;22(1):48-56. doi: 10.1111/jtm.12164. Epub 2014 Oct 13. J Travel Med. 2015. PMID: 25308927 Free article. Clinical Trial.

10

A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.

Reisinger KS, Holmes SJ, Pedotti P, Arora AK, Lattanzi M. Reisinger KS, et al. Hum Vaccin Immunother. 2014;10(8):2395-407. doi: 10.4161/hv.29393. Hum Vaccin Immunother. 2014. PMID: 25424947 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,303 results

Search Page